{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:29:44Z","timestamp":1767652184273,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.clgc.2016.07.018","type":"journal-article","created":{"date-parts":[[2016,7,29]],"date-time":"2016-07-29T07:32:01Z","timestamp":1469777521000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["A Systematic Review of the Incidence and Risk Factors for Taxane Acute Pain Syndrome in Patients Receiving Taxane-Based Chemotherapy for Prostate Cancer"],"prefix":"10.1016","volume":"15","author":[{"given":"Ricardo","family":"Fernandes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasha","family":"Mazzarello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Risa","family":"Shorr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed F.K.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5178-7307","authenticated-orcid":false,"given":"Carmel","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Ong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2016.07.018_bib1","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nrd3253","article-title":"Microtubule-binding agents: a dynamic field of cancer therapeutics","volume":"9","author":"Dumontet","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clgc.2016.07.018_bib2","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.07.018_bib3","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1093\/annonc\/mdt194","article-title":"Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial","volume":"24","author":"Bahl","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.07.018_bib4","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2016.07.018_bib5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1349-7006.2006.00166.x","article-title":"Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients","volume":"97","author":"Minami","year":"2006","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clgc.2016.07.018_bib6","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1200\/JCO.2010.33.0308","article-title":"Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1","volume":"29","author":"Loprinzi","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.07.018_bib7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3747\/co.v17i4.562","article-title":"Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey","volume":"17","author":"Saibil","year":"2010","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clgc.2016.07.018_bib8","first-page":"1583","article-title":"Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy\u2014a systematic review","volume":"24","author":"Fernandes","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clgc.2016.07.018_bib9","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1002\/cncr.27489","article-title":"Further data supporting that the paclitaxel-associated acute pain syndrome is associated with the development of peripheral neuropathy: NCCTG trial N08C1","volume":"118","author":"Reeves","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2016.07.018_bib10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/PPO.0b013e31815a999b","article-title":"The paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism","volume":"13","author":"Loprinzi","year":"2007","journal-title":"Cancer J"},{"key":"10.1016\/j.clgc.2016.07.018_bib11","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/0959-8049(94)90182-1","article-title":"The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress","volume":"30A","author":"Portenoy","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2016.07.018_bib12","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/cncr.11578","article-title":"Measuring the side effects of taxane therapy in oncology: the Functional Assessment of Cancer Therapy\u2013Taxane (FACT-Taxane)","volume":"98","author":"Cella","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2016.07.018_bib13","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1200\/JCO.2004.99.298","article-title":"Use of gabapentin in the prevention of taxane-induced arthralgias and myalgias","volume":"22","author":"Nguyen","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.07.018_bib14","first-page":"274","article-title":"Glutamine does not prevent paclitaxel-associated myalgias and arthralgiasas","volume":"1","author":"Jacobson","year":"2003","journal-title":"J\u00a0Support Oncol"},{"key":"10.1016\/j.clgc.2016.07.018_bib15","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1200\/JCO.1999.17.10.3038","article-title":"Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer","volume":"17","author":"Gelmon","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2016.07.018_bib16","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/cncr.28654","article-title":"NCCTG N08CA (Alliance): the use of glutathione for prevention of paclitaxel\/carboplatin induced peripheral neuropathy: a phase III randomized, double-blind placebo-controlled study and for the Alliance for Clinical Trials in Oncology","volume":"120","author":"Leal","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2016.07.018_bib17","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clgc.2016.07.018_bib18","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.jclinepi.2008.10.012","article-title":"An evidence-based practice guideline for the peer review of electronic search","volume":"62","author":"Sampson","year":"2009","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.clgc.2016.07.018_bib19","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ejca.2013.11.034","article-title":"Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15)","volume":"50","author":"Gravis","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2016.07.018_bib20","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S1470-2045(13)70294-8","article-title":"Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial","volume":"14","author":"Quinn","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2016.07.018_bib21","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/pcan.2012.13","article-title":"Toxicity in patients receiving adjuvant docetaxel\u00a0+ hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial","volume":"15","author":"Kellokumpu-Lehtinen","year":"2012","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2016.07.018_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(12)70537-5","article-title":"2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial","volume":"14","author":"Kellokumpu-Lehtinen","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2016.07.018_bib23","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.clgc.2016.07.018_bib24","unstructured":"Taxane acute pain syndrome (TAPS) in patients receiving taxane chemotherapy for breast or prostate cancer (TAPS OTT 14-06). NCT 02362087. Available at: www.ClinicalTrials.gov. Accessed: April 1, 2016."}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876731630221X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876731630221X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:26:58Z","timestamp":1761564418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876731630221X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S155876731630221X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2016.07.018","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Systematic Review of the Incidence and Risk Factors for Taxane Acute Pain Syndrome in Patients Receiving Taxane-Based Chemotherapy for Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2016.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}